Welcome to our dedicated page for Rxsight news (Ticker: RXST), a resource for investors and traders seeking the latest updates and insights on Rxsight stock.
RxSight, Inc. (NASDAQ: RXST) is an ophthalmic medical device company whose news flow centers on its Light Adjustable Lens system and corporate developments related to cataract surgery care. Company press releases describe RxSight as dedicated to providing high-quality customized vision to patients following cataract surgery through its Light Adjustable Lens (LAL/LAL+) and Light Delivery Device (LDD) platform.
News updates for RXST commonly include financial and operating results, such as quarterly revenue, procedure volumes for Light Adjustable Lenses, and the number of Light Delivery Devices sold and installed. These releases often discuss trends in LAL procedure volumes, changes in the installed base of LDDs, and guidance ranges for revenue and gross margin. Investors and observers can use these announcements to track how adoption of the Light Adjustable Lens system is progressing across cataract practices.
RxSight’s news also highlights corporate and leadership developments, including transitions in the Chief Financial Officer role and appointments to the Board of Directors and Board committees, as disclosed in press releases and related Form 8-K filings. In addition, the company regularly announces participation in major healthcare and ophthalmology conferences, where management presents to investors and engages with surgeons and other stakeholders.
Another recurring theme in RxSight’s news is commercial and clinical engagement activity. The company has reported initiatives such as practice development programs and Live Learning Sessions at ophthalmology meetings, where surgeons share real-world experience with the Light Adjustable Lens and discuss clinical and practice-level impacts.
This RXST news page aggregates these types of updates in one place, allowing readers to follow RxSight’s reported financial performance, leadership changes, conference participation, and initiatives related to its Light Adjustable Lens technology over time.
RxSight, Inc., an ophthalmic medical device company, announced the addition of three new members to its Board of Directors effective August 3, 2021, following its IPO. New board members include Robert Palmisano, Robert Warner, and Julie Andrews, who bring extensive experience in commercial operations and finance. Concurrently, four longstanding board members resigned. RxSight aims to enhance patient vision post-cataract surgery with its innovative Light Adjustable Lens technology. The company expresses optimism regarding its future growth and transformation in the cataract surgery market.
RxSight, Inc. has completed its initial public offering (IPO) of 7,350,000 shares of common stock at $16.00 per share, generating approximately $132 million in gross proceeds. The offering includes the underwriters’ option to purchase an additional 898,594 shares, bringing the total to 8,248,594 shares sold. The shares started trading on Nasdaq under the symbol RXST on July 30, 2021. RxSight specializes in ophthalmic medical devices, particularly the innovative Light Adjustable Lens system designed to enhance patients' vision post-cataract surgery.
RxSight, an ophthalmic medical device company, has priced its initial public offering at $16.00 per share, raising approximately $117.6 million from the sale of 7,350,000 shares. The offering is set to close on August 3, 2021, pending customary closing conditions. Additionally, underwriters have a 30-day option to purchase up to 1,102,500 shares. Trading on the Nasdaq will commence on July 30, 2021, under the ticker symbol RXST. This IPO marks a significant step for RxSight, as it aims to enhance the experience of patients post-cataract surgery.